JP2023524813A5 - - Google Patents

Info

Publication number
JP2023524813A5
JP2023524813A5 JP2022567561A JP2022567561A JP2023524813A5 JP 2023524813 A5 JP2023524813 A5 JP 2023524813A5 JP 2022567561 A JP2022567561 A JP 2022567561A JP 2022567561 A JP2022567561 A JP 2022567561A JP 2023524813 A5 JP2023524813 A5 JP 2023524813A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
cancer
alkyl
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2022567561A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023524813A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/031301 external-priority patent/WO2021226460A1/en
Publication of JP2023524813A publication Critical patent/JP2023524813A/ja
Publication of JP2023524813A5 publication Critical patent/JP2023524813A5/ja
Withdrawn legal-status Critical Current

Links

JP2022567561A 2020-05-08 2021-05-07 免疫調節剤 Withdrawn JP2023524813A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063021924P 2020-05-08 2020-05-08
US63/021,924 2020-05-08
PCT/US2021/031301 WO2021226460A1 (en) 2020-05-08 2021-05-07 Immunomodulators

Publications (2)

Publication Number Publication Date
JP2023524813A JP2023524813A (ja) 2023-06-13
JP2023524813A5 true JP2023524813A5 (enExample) 2024-05-09

Family

ID=76181284

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022567561A Withdrawn JP2023524813A (ja) 2020-05-08 2021-05-07 免疫調節剤

Country Status (6)

Country Link
US (1) US20230242585A1 (enExample)
EP (1) EP4146670A1 (enExample)
JP (1) JP2023524813A (enExample)
KR (1) KR20230008790A (enExample)
CN (1) CN115916340A (enExample)
WO (1) WO2021226460A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022221284A2 (en) * 2021-04-12 2022-10-20 Bristol-Myers Squibb Company Cyclic peptide immunomodulators
TW202430537A (zh) * 2022-10-20 2024-08-01 日商中外製藥股份有限公司 環狀胜肽的結晶的製造方法

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US5374548A (en) 1986-05-02 1994-12-20 Genentech, Inc. Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor
MX9203291A (es) 1985-06-26 1992-08-01 Liposome Co Inc Metodo para acoplamiento de liposomas.
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US5108921A (en) 1989-04-03 1992-04-28 Purdue Research Foundation Method for enhanced transmembrane transport of exogenous molecules
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US9308236B2 (en) * 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
WO2016039749A1 (en) * 2014-09-11 2016-03-17 Bristol-Myers Squibb Company Macrocyclic inhibitors of the pd-1/pd-l1 and cd80 (b7-1)/pd-li protein/protein interactions
US9856292B2 (en) * 2014-11-14 2018-01-02 Bristol-Myers Squibb Company Immunomodulators
EP3642220A1 (en) * 2017-06-23 2020-04-29 Bristol-Myers Squibb Company Immunomodulators acting as antagonists of pd-1
WO2021102143A1 (en) * 2019-11-19 2021-05-27 Bristol-Myers Squibb Company Macrocyclic peptides as pd-l1 inhibitors and immunomodulators for the treatment of cancer and infectious diseases

Similar Documents

Publication Publication Date Title
JP2020515574A5 (enExample)
JP2023510737A5 (enExample)
JP2023510736A5 (enExample)
US12194040B2 (en) FAK inhibitor and drug combination thereof
JP2013539795A5 (enExample)
JP2013512263A5 (enExample)
JP2019512478A5 (enExample)
JP2020525429A5 (enExample)
JP2020532529A5 (enExample)
JP2016503414A5 (enExample)
JP2020503247A5 (enExample)
JP2014525464A5 (enExample)
JP2023503050A5 (enExample)
JP2013512264A5 (enExample)
JP2019513734A5 (enExample)
JP2023524813A5 (enExample)
HK1221717A1 (zh) 取代的苄基吡唑
JP2019534865A5 (enExample)
JP2016526540A5 (enExample)
CN107548391A (zh) 嘧啶或吡啶类化合物、其制备方法和医药用途
EP3191493B1 (en) Nitrogen-containing analogs of salinomycin, synthesis and use against cancer stem cells and malaria
JP2013512268A5 (enExample)
CA2987978A1 (en) Novel compounds as dual inhibitors of histone methyltransferases and dna methyltransferases
JP2013199483A5 (enExample)
WO2021120717A1 (zh) 抗癌化合物及其医药用途